Credit of winners of the laboratory services of the national elites foundation will increase to 30 billion rials
Credit of winners of the laboratory services of the national elites foundation will increase to 30 billion rials
Inflammation signals induce dormancy in aging brain stem cells
In old age, the amount of stem cells in the brains of mice decreases drastically. The remaining ones protect themselves from completely vanishing by entering a state of dormancy, scientists from the German Cancer Research Center (DKFZ) have now reported in Cell.
Scott Gottlieb returns to NEA – this time with some valuable regulatory experience under his belt
One of the largest venture capital firms in the world is adding an enviable member to its healthcare investment team: the man who just stepped down as commissioner of the Food and Drug Administration.
Long-Term Study Shows Endothelial Progenitor Cells Are Safe for Treating Stroke Patients
A new study recently published in STEM CELLS Translational Medicine demonstrates the long-term safety of laboratory-expanded endothelial progenitor cells for treating ischemic stroke. This could be good news for the 15 million people who, according to to the World Stroke Organization, suffer from this dangerous condition each year.
Kidney-Resident Macrophages — a role for Healing During Acute Kidney Injury
During development in the womb, immune cells called macrophages go to the kidneys and remain there for life. Understanding the possible healing role for these macrophages after kidney damage may be crucial to helping treat patients who suffer acute kidney injury.
Novartis CEO plans gene therapy price far lower than $4 million to $5 million range
Novartis AG’s top executive said on Wednesday it expects to price its gene therapy for spinal muscular atrophy “far lower” than the $4 million to $5 million figure the Swiss drugmaker has said it could be worth.
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
AveXis, a Novartis company, today announced the US Food and Drug Administration (FDA) has approved Zolgensma® (onasemnogene abeparvovac-xioi) for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.
Johns Hopkins Researchers Create Novel Cell Model of Aging-Related Colon Cancer Risk
Johns Hopkins Kimmel Cancer Center researchers say a new study of clusters of mouse cells known as “organoids” has significantly strengthened evidence that epigenetic changes, common to aging, play a essential role in colon cancer initiation.
The number of knowledge-based products in the field of stem cells has increased
Today, more than 80 knowledge-based companies are active in the field of stem cells, entrance of products of which to the society has increased hope in patients.
Medical equipment of Iran will be exhibited in the largest fair of the world
The 5th national pavilion of Iranian products will be held in medical equipment exhibition (MEDICA) in Dusseldorf, Germany.
